Paradigm Genetics Signs Two-Year Extension With Bayer CropScience
20-Nov-2003
Paradigm genetics, Inc. announced that it has signed a two-year extension of its herbicide discovery collaboration with Bayer CropScience, which would take the partnership through September 2006. This extension, the second since the initiation of this program, is structured similarly to the base contract, to include research funds and success fees for assay deliveries.
"We are very pleased that Bayer has elected to extend our collaboration into 2006. This agreement underscores the vital role we play in their herbicide discovery program and is a strong validation of the sustained value of our research capabilities," said Heinrich Gugger, Ph.D., President and CEO for Paradigm Genetics. "This extension will allow us to further exploit for Bayer the large number of validated herbicide targets discovered during this collaboration."
"Our decision to extend this partnership with Paradigm Genetics was based on the high level of success we have had to date with this program," said Dr. Klaus Stenzel, Head of Global Target Research of Bayer CropScience. "We've been impressed with the quantity and quality of targets and assays Paradigm has delivered. Together we are building a strong proprietary position to secure the use of important genomic technologies in herbicide research."
Paradigm's herbicide partnership with Bayer began in October 1998 with the objective of discovering a portfolio of novel herbicide products that will be developed and marketed by Bayer. The term of the original agreement was three years with an initial option to extend the relationship another two. The first extension was signed in September 2001. To date, Paradigm has analyzed thousands of plant genes, identified hundreds of novel herbicide targets and delivered numerous assays for use in Bayer CropScience's high throughput chemical screening facility. Payments to Paradigm include committed research funds, fees for assays delivered and milestone payments. The agreement includes success fees and possible royalty payments to Paradigm for any commercial herbicides that might emerge from the collaboration.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
